Abstract: Described are a sterile, ready-to-use, pharmaceutical oil-in water emulsion compositions for parenteral administration comprising: 0.015 to 1.2% wt/vol of progestogen; 0.5-30% wt/vol oil, wherein the oil comprises at least 85% wt/wt triglyceride; 0.0425-12.5% wt/vol phospholipid; 61.4-99.4% wt/vol aqueous medium; wherein the phospholipid is present in an amount of 6.8%-43% of the oil (wt/wt), and wherein the progestogen is present in an amount greater than or equal to 2.1 wt % of the oil. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.

Abstract: Described are sterile, ready-to-use, pharmaceutical oil-in-water emulsion compositions for parenteral administration comprising: 0.015 to 0.5% wt/vol progesterone; 0.5 to 10% wt/vol oil, wherein the oil comprises at least 85% wt./wt. triglyceride; 0.0425 to 4.1% wt/vol phospholipid; 80-99.4% wt/vol aqueous medium; wherein the composition has an osmolality in the range of 200-1000 mOsm/kg. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.

Abstract: Described are sterile, ready-to-use, pharmaceutical oil-in-water emulsion compositions for parenteral administration comprising: 0.015 to 0.5% wt/vol progesterone; 0.5 to 10% wt/vol oil, wherein the oil comprises at least 85% wt./wt. triglyceride; 0.0425 to 4.1% wt/vol phospholipid; 80-99.4% wt/vol aqueous medium; wherein the composition has an osmolality in the range of 200-1000 mOsm/kg. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.

Abstract: Described are a sterile, ready-to-use, pharmaceutical oil-in water emulsion compositions for parenteral administration comprising: 0.015 to 1.2% wt/vol of progestogen; 0.5-30% wt/vol oil, wherein the oil comprises at least 85% wt/wt triglyceride; 0.0425-12.5% wt/vol phospholipid; 61.4-99.4% wt/vol aqueous medium; wherein the phospholipid is present in an amount of 6.8%-43% of the oil (wt/wt), and wherein the progestogen is present in an amount greater than or equal to 2.1 wt % of the oil. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.

Abstract: Described are a sterile, ready-to-use, pharmaceutical oil-in water emulsion compositions for parenteral administration comprising: 0.015 to 1.2% wt/vol of progestogen; 0.5-30% wt/vol oil, wherein the oil comprises at least 85% wt/wt triglyceride; 0.0425-12.5% wt/vol phospholipid; 61.4-99.4% wt/vol aqueous medium; wherein the phospholipid is present in an amount of 6.8%-43% of the oil (wt/wt), and wherein the progestogen is present in an amount greater than or equal to 2.1 wt % of the oil. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.

Abstract: Described are a sterile, ready-to-use, pharmaceutical oil-in water emulsion compositions for parenteral administration comprising: 0.015 to 1.2% wt/vol of progestogen; 0.5-30% wt/vol oil, wherein the oil comprises at least 85% wt/wt triglyceride; 0.0425-12.5% wt/vol phospholipid; 61.4-99.4% wt/vol aqueous medium; wherein the phospholipid is present in an amount of 6.8%-43% of the oil (wt/wt), and wherein the progestogen is present in an amount greater than or equal to 2.1 wt % of the oil. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.

Abstract: Described are sterile, ready-to-use, pharmaceutical oil-in-water emulsion compositions for parenteral administration comprising: 0.015 to 0.5% wt/vol progesterone; 0.5 to 10% wt/vol oil, wherein the oil comprises at least 85% wt./wt. triglyceride; 0.0425 to 4.1% wt/vol phospholipid; 80-99.4% wt/vol aqueous medium; wherein the composition has an osmolality in the range of 200-1000 mOsm/kg. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.